A type of gene therapy that reintroduces wild-type p53 using an adenoviral vector, often in the form of a vaccine, has been tested in preclinical studies and clinical trials for a wide array of malignancies [31,32,33], including PCa [34,35]. The gene discussed is TP53; the disease is posterior cortical atrophy.